

Medicaid Preferred Drug List (PDL) Program
Special Session: Review of Antidepressants and Antianxiety Medications
Pharmacy and Therapeutics Committee Meeting
Wednesday, October 6, 2004
1:00 p.m., DMAS Board Room
DRAFT AGENDA

Meeting Purpose: Pursuant to the 2004 Appropriations Act (Item 326 BB 7), the Department of Medical Assistance Services has requested that the Pharmacy and Therapeutics Committee review antidepressants and antianxiety drug classes for potential inclusion on the preferred drug list (PDL). Public comments from all interested parties will be accepted during this meeting. If the Committee recommends inclusion of these classes on the PDL, a report will be prepared for submission to the Governor, Chairmen of the House Appropriations and Senate Finance Committees and the Joint Commission on Health Care on January 1, 2005. If recommended for inclusion, the effective date would be no earlier than July 1, 2005.

- **Welcome and Introductions** Patrick W. Finnerty, Director
- **Comments from the Secretary of Health and Human Resources** The Honorable Jane H. Woods, Secretary of Health and Human Resources
- **Comments from the Chairperson** Randy Axelrod, M.D., Chairman
- **Acceptance of Minutes from September 20, 2004 Meeting** P&T Committee Members
- **Confidential Meeting** Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information
- **Drug Class and Criteria Discussions:** P&T Committee Members
 - HMG CoA Reductase Inhibitors (Statins)
 - Selective Cox-2 Inhibitors
- **Drug Class Discussions and Public Comments** P&T Committee Members
 - **Antidepressants**
 - Selective Serotonin Reuptake Inhibitors (SSRIs)
 - Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Other Antidepressants
 - **Antianxiety Drugs**
 - Benzodiazepine
 - Other Classes
- **P&T Committee Discussion** Randy Axelrod, M.D.
P&T Committee Members
- **Open Issues** Randy Axelrod, M.D., Chairman
- **Next Meeting – March 2005** Randy Axelrod, M.D., Chairman

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present information on the specific drug classes that are listed on the Agenda. Each speaker will be allocated to a 3-minute time slot. The actual speakers and number of speakers will be decided by the Chairperson based on relevancy of the information.

If you are interested in presenting, please submit your written comments or an outline of discussion points, indicate your request to speak at the meeting and the name of the presenter. Please submit your request to present to pdlinput@dmas.virginia.gov by COB Friday, September 30, 2004. **Please note that all presentation requests must receive a confirmation number from the PDL email address to verify inclusion on the speakers' list. In addition, there will be an opportunity to register for presentations up to ten minutes prior to the start of the meeting.**

Written information/presentations: The P&T Committee will accept written comments for consideration. Please send information to pdlinput@dmas.virginia.gov by COB Friday, September 30, 2004.